Stock RAD RADIOPHARM THERANOSTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Market Closed - Australian S.E.
Other stock markets
 07:10:13 28/06/2024 BST 		5-day change 1st Jan Change
0.038 AUD -7.32% Intraday chart for Radiopharm Theranostics Limited +11.76% -48.65%
06-25 Radiopharm Theranostics Raises AU$70 Million to Fund Clinical Programs; Shares Jump 24% MT
06-20 US Radiopharmaceutical Firm to Invest Up to AU$18 Million into Radiopharm Theranostics MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Radiopharm Theranostics Raises AU$70 Million to Fund Clinical Programs; Shares Jump 24%
MT
Radiopharm Receives Strategic Investment for up to A$18 million
AQ
US Radiopharmaceutical Firm to Invest Up to AU$18 Million into Radiopharm Theranostics
MT
Radiopharm Theranostics Limited announced that it has received AUD 7.481259 million in funding from Lantheus Holdings, Inc.
CI
Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities
MT
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study
MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate
MT
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%
MT
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement
MT
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site
MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial
MT
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer
MT
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.
CI
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.
CI
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%
MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial
MT
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer
AQ
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%
MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RAD Stock
  4. News Radiopharm Theranostics Limited